fruquintinib + trifluridine + tipiracil

**fruquintinib + trifluridine + tipiracil** is an investigational oral combination therapy used in the treatment of refractory metastatic colorectal cancer (mCRC). It combines **fruquintinib**, a highly selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), and **trifluridine/tipiracil** (TAS-102), an oral antineoplastic agent that consists of trifluridine, a nucleoside analog that is incorporated into DNA and causes DNA dysfunction, and tipiracil, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine. The combination acts through dual mechanisms: anti-angiogenesis (via VEGFR inhibition) and direct cytotoxicity to tumor cells (via impairment of DNA synthesis and function). This strategy is being explored primarily in patients who have failed at least two prior lines of standard therapy for mCRC and has demonstrated promising efficacy with manageable safety in early clinical studies and phase 2 trials[1][2][4][5][7].

Brand names

Fruzaqla (fruquintinib)Elunate (fruquintinib)Lonsurf (trifluridine + tipiracil)

Other names

trifluridine/tipiracil plus fruquintinibFTD/TPI plus fruquintinibTAS-102 plus fruquintinibTAS102 plus fruquintinibTAS 102 plus fruquintinib